ダウンロード数: 343
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
30_545.pdf | 7.8 MB | Adobe PDF | 見る/開く |
タイトル: | 前立腺癌に対する(D-Leu6)-des Gly-NH210-LH・RH ethylamide (Leuprolide)の臨床効果 |
その他のタイトル: | Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer |
著者: | 山中, 英寿 ![]() 牧野, 武雄 ![]() 熊坂, 文成 ![]() 志田, 圭三 ![]() |
著者名の別形: | YAMANAKA, Hidetoshi MAKINO, Takeo KUMASAKA, Fuminari SHIDA, Keizo |
キーワード: | Prostatic cancer LH.RH agonist |
発行日: | Apr-1984 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 30 |
号: | 4 |
開始ページ: | 545 |
終了ページ: | 560 |
抄録: | The clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH X RH ethylamide (Leuprolide) against prostatic cancer was evaluated at the end of twelve weeks of administration of a daily dose of 20 mg subcutaneous injection to 22 patients with prostatic cancer. Of these 22 patients, 19 were previously non-treated and 3 had reactivated cancer. Complete regression was obtained in all patients with stage B or C cancer. Also, in 5 out of 12 previously non-treated patients with stage D cancer, Leuprolide administration proved to be effective for controlling prostatic cancer. However, Leuprolide therapy produced only stable effects at best in 3 patients who had reactivated cancer. It has no side effect and should be recommended as a drug of first choice in the treatment of previously non-treated prostatic cancer. It can be assumed from the present studies that the efficacy of this agent against prostatic cancer is mainly the result of its inhibitory effect on hypothalamo-pituitary testicular system, i.e., a medical castration effect. |
URI: | http://hdl.handle.net/2433/118151 |
PubMed ID: | 6435416 |
出現コレクション: | Vol.30 No.4 |
![](/dspace/image/articlelinker.gif)
このリポジトリに保管されているアイテムはすべて著作権により保護されています。